SUTRO BIOPHARMA, INC.
About SUTRO BIOPHARMA, INC.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $102.5M
- Net income
- -$191.1M
- Total assets
- $173.8M
- Market cap
- $432.3M
- Operating margin
- -154.5%
- Net margin
- -186.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $102.5M
- Operating expenses
- $260.9M
- Operating income
- -$158.4M
- Income tax
- -$93.0K
- Net income
- -$191.1M
- EPS (basic)
- $-22.49
- EPS (diluted)
- $-22.49
Balance sheet
- Total assets
- $173.8M
- Current assets
- $150.9M
- Total liabilities
- $306.3M
- Current liabilities
- $75.1M
- Shareholders’ equity
- -$132.5M
Cash flow
- Operating cash flow
- -$177.2M
- Investing cash flow
- $45.0M
- Financing cash flow
- $44.0K
- Net cash flow
- -$132.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $432.3M
- EPS (diluted)
- $-22.49
- Shares outstanding
- 17.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 27, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $191.1M in FY2025.
- Revenue grew 66% from FY2021 to FY2025.
- Trading 38% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SUTRO BIOPHARMA, INC..
Write a review
News about SUTRO BIOPHARMA, INC.
News & sentiment via Polygon.io
